NUR 600 Module 3 Assignment Draft of Project Bradley University Paper Instructions For this week, please present a draft/outline of your PowerPoint project (see Module 5 Assignment).

Background The FDA has approved gabapentin, also referred to as Neurontin, for the treatment of neuralgia postherpetic and seizures with partial onset. Comparable efficacy to carbamazepine and tricyclic antidepressants has been observed in clinical trials (Russo et al., 2022).

Additionally, chronic back pain, neuropathic cancer pain, and HIV infection pain are treated with it. While the precise mechanism by which it operates remains unknown, this substance is generally well-tolerated, titratable, and does not necessitate laboratory monitoring. Gabapentin-eligible patients must exhibit a distinct neuropathic pain syndrome.

Objective The objective of this capstone project is to evaluate the efficacy of gabapentin as a treatment for adult chronic pain (De Leeuw et al., 2019).
Rationale Neuropathic pain is a difficult condition that can render individuals permanently disabled.

Treatment frequently involves a combination of physical and pharmacological interventions. Standard analgesics such as paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs) are deemed ineffective, although topical lidocaine patches and capsaicin may provide relief for some individuals (Horne et al., 2020).

‘Unconventional analgesics’ such as antidepressants and antiepileptics are frequently employed in treatment. Gabapentin is commonly prescribed as an initial-line treatment for neuropathic pain; nevertheless, it has been associated with a low rate of effectiveness and a significant likelihood of adverse events (Puljak, 2020).

Design and Methodology The project will use a thorough literature review design to analyze randomized controlled trials conducted between 2019 and 2024, comparing the effectiveness of gabapentin with placebo among other active therapies for neuropathic pain. Data will be gathered and examined to assess significant or moderate pain reduction.

Chi-squared tests will be used for comparison, and findings will be presented simply and academically, including a table showing all outcome measurements (Mathieson et al., 2020).

Expected Results Gabapentin can alleviate the pain associated with peripheral diabetic neuropathy and postherpetic neuralgia when administered daily at high doses ranging from 1800 to 3600 milligrams.

However, there is limited evidence regarding other forms of neuropathic pain. An adverse effect of a 50% reduction in pain intensity is associated with improvements in function, work, sleep quality, fatigue, depression, and overall well-being (Verret et al., 2020). More than half may encounter adverse events.

Conclusion

Gabapentin is effective for some individuals suffering from persistent neuropathic pain. It is impossible to predict in advance who will gain advantages and who might not. Current understanding indicates that a brief trial is the most effective method of determining.

References

• De Leeuw, T. G., Mangiarini, L., Lundin, R., Kaguelidou, F., Van Der Zanden, T., Della Pasqua, O., Tibboel, D., Ceci, A., & De Wildt, S. N. (2019). Gabapentin as an add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years – evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation study protocol for a randomized controlled trial. Trials, 20(1). https //doi.org/10.1186/s13063-018-3169-3